Download MendeleySelective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients.
Yuda, J., Will, C., Phillips, D.C., Abraham, L., Alvey, C., Avigdor, A., Buck, W., Besenhofer, L., Boghaert, E., Cheng, D., Cojocari, D., Doyle, K., Hansen, T.M., Huang, K., Johnson, E.F., Judd, A.S., Judge, R.A., Kalvass, J.C., Kunzer, A., Lam, L.T., Li, R., Martin, R.L., Mastracchio, A., Mitten, M., Petrich, A., Wang, J., Ward, J.E., Zhang, H., Wang, X., Wolff, J.E., Bell-McGuinn, K.M., Souers, A.J.(2023) Commun Med (Lond) 3: 154-154
- PubMed: 37880389
- DOI: https://doi.org/10.1038/s43856-023-00380-z
- Primary Citation of Related Structures:
8EKX, 8EL0, 8EL1 - PubMed Abstract:
MCL-1 is a prosurvival B-cell lymphoma 2 family protein that plays a critical role in tumor maintenance and survival and can act as a resistance factor to multiple anticancer therapies. Herein, we describe the generation and characterization of the highly potent and selective MCL-1 inhibitor ABBV-467 and present findings from a first-in-human trial that included patients with relapsed/refractory multiple myeloma (NCT04178902).
Organizational Affiliation:
National Cancer Center Hospital East, Kashiwa, Japan.
